Medrx - Japan Biotech Microcap in Potential Big Licensing Deal

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Equity Bottom-Up

<p style="text-align: justify;">On the surface, <a href="https://www.smartkarma.com/entities/13514" target="_blank" data-smartkarma-citation="entities:13514:1">Peptidream's (4587 JP)</a> deal with <a href="https://www.smartkarma.com/entities/1132" target="_blank" data-smartkarma-citation="entities:1132:1">Johnson &amp; Johnson's (JNJ US)</a> Janssen unit looks no different from the deals they have cut with other firms, with the exception of the total milestone payments. Normally, this is undisclosed, but in this instance, it has been announced – it is US$1.15bil – possibly because it is too large a number to be kept from investors, which is why the shares soared on Monday.  The deal sees J&amp;J access Peptidream's peptide drug conjugate capabilities as well…</p>

On the surface, Peptidream's (4587 JP) deal with Johnson &amp; Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with other firms, with the exception of the total milestone payments. Normally, this is undisclosed, but in this instance, it has been announced – it is US$1.15bil – possibly because it is too large a number to be kept from investors, which is why the shares soared on Monday.  The deal sees J&amp;J access Peptidream's peptide drug conjugate capabilities as well…

PeptiDream: J&J Latest Drug Major to Tie Up

Peptidream Inc

PeptiDream: J&J Latest Drug Major to Tie Up